TABLE 3.
Pharmacokinetic parameters for patients treated with 10 mg/kg weekly
| Time point | Statistic | AUC(0‐inf) (mg.h/L) | AUC(0‐tau) (mg.h/L) | C max (mg/L) | C min (mg/L) | t ½ (h) | MRT(0‐inf) (h) | CL (L/h) | V dss (L) |
|---|---|---|---|---|---|---|---|---|---|
| Cycle 1, day 1 | n | 27 | 27 | 28 | ‐ | 27 | 27 | 27 | 27 |
| Mean | 19910 | 14490 | 231.11 | ‐ | 87.00 | 124.8 | 0.04058 | 4.837 | |
| SD | 6826 | 4437 | 93.82 | ‐ | 20.06 | 29.16 | 0.01259 | 1.045 | |
| CV% | 34.3 | 30.6 | 40.6 | ‐ | 23.1 | 23.4 | 31.0 | 21.6 | |
| Minimum | 9930 | 8650 | 122.0 | ‐ | 56.0 | 79.3 | 0.0208 | 3.12 | |
| Median | 18420 | 13510 | 213.00 | ‐ | 85.60 | 122.5 | 0.03930 | 4.772 | |
| Maximum | 36400 | 24100 | 621.0 | ‐ | 150 | 214 | 0.0770 | 6.97 | |
| Geometric mean | 18870 | 13890 | 218.33 | ‐ | 84.97 | 121.8 | 0.03883 | 4.727 | |
| Geometric CV% | 34.0 | 30.0 | 33.2 | ‐ | 22.4 | 22.8 | 30.9 | 22.4 | |
| Cycle 2, day 15 | n | ‐ | 18 | 18 | 18 | 18 | ‐ | 18 | 18 |
| Mean | ‐ | 26320 | 313.83 | 83.78 | 118.3 | ‐ | 0.03152 | 5.122 | |
| SD | ‐ | 9925 | 76.70 | 39.15 | 32.32 | ‐ | 0.01050 | 1.599 | |
| CV% | ‐ | 37.7 | 24.4 | 46.7 | 27.3 | ‐ | 33.3 | 31.2 | |
| Minimum | ‐ | 13500 | 169.0 | 33.9 | 72.7 | ‐ | 0.0182 | 2.93 | |
| Median | ‐ | 26250 | 321.50 | 83.05 | 120.3 | ‐ | 0.02929 | 5.028 | |
| Maximum | ‐ | 50500 | 476.0 | 156.0 | 176 | ‐ | 0.0568 | 8.33 | |
| Geometric mean | ‐ | 24600 | 304.41 | 74.77 | 113.8 | ‐ | 0.02998 | 4.892 | |
| Geometric CV% | ‐ | 39.6 | 26.5 | 53.9 | 29.5 | ‐ | 33.3 | 32.2 |
Abbreviations: AUC(0‐inf), area under the curve from time 0 to infinity; AUC(0‐tau), area under the curve to the end of the dosing period; CL, clearance; C max, maximum observed concentration; C min, minimum observed concentration; CV, coefficient of variation; MRT(0‐inf), mean residence time from time 0 to infinity; t ½, half‐life; SD, standard deviation; V dss, volume of distribution at steady state.